Genetically proxied IL-13 inhibition is associated with risk of psoriatic disease: Mendelian randomization study.

Sizheng Steven ZhaoKimme HyrichZenas YiuAnne BartonJohn Bowes

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2024)

We provide supportive genetic evidence that IL-13i is linked to increased risk of PsA and psoriasis. Physicians prescribing IL-13 inhibitors should be vigilant for these adverse events.

Keyphrases

primary care
prostate cancer
rheumatoid arthritis
ankylosing spondylitis
hidradenitis suppurativa